1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1221,
2000,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1221,
2000,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1221,
2000,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
4. |
Ciprofloxacin preferable for acute exacerbations of chronic bronchitis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1221,
2000,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
5. |
Ecopipam: calming cocaine cravings |
|
Inpharma Weekly,
Volume &NA;,
Issue 1221,
2000,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
6. |
New drug dramatically effective against chronic myelogenous leukaemia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1221,
2000,
Page 7-7
Carmen Innes,
Preview
|
|
摘要:
An exciting new drug to treat chronic myelogenous leukaemia (CML) stole the show at the 41st Annual Meeting of the American Society of Hematology [New Orleans, US; December 1999]. Not just researchers, but even the national news bulletins were hailing STI 571 [CGP 57148B; CTI 571], a Bcr-Abl inhibitor in early clinical trials, as the most promising treatment for the disease since the introduction of interferon several years ago. And although very preliminary, the results of a trial presented at the meeting appear to support their claims - 100% of patients treated at dosages of 300mg or higher had a complete haematological response to STI 571 therapy.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
7. |
'Encouraging'results with decitabine in CML |
|
Inpharma Weekly,
Volume &NA;,
Issue 1221,
2000,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1221,
2000,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1221,
2000,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
10. |
Gemcitabine regimens improve response rates in colorectal cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1221,
2000,
Page 11-11
Charles Bankhead,
Preview
|
|
摘要:
Gemcitabine regimens show promise for improving response rates in colorectal cancer, according to new data presented at the Chemotherapy Foundation Symposium [New York, US; November 1999]. In one study, the combination of irinotecan and gemcitabine demonstrated activity in patients with advanced colorectal cancer. In a second study, the combination of gemcitabine, fluorouracil [5-FU] and folinic acid [leucovorin] lead to major objective responses or stable disease in almost half the patients treated, including patients with prior exposure to fluorouracil.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|